A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...

Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Under US law, compounding pharmacies can make and sell patent ... and other obesity therapies like Novo Nordisk's Wegovy (semaglutide), which remains on the shortages list. After deciding that ...

President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland ...

Hims & Hers Health ( HIMS 6.30%) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. The telehealth ...

The FDA gave compounding pharmacies 60 to 90 days ... A few pills have emerged, however: Novo sells a pill form of ...

Compounding pharmacies have revolutionized the way medications are tailored to meet individual needs. Unlike traditional ...

PHOENIX (AZFamily) — Weight loss drugs have taken the world by storm, but high demand has created a shortage and a new opportunity for compounding pharmacies to make their own version of them at ...

The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...